GTU-MultiHIV B-clade

Developed for: HIV infectious disease
Investigated by: Imperial College London · ANRS, Emerging Infectious Diseases · CUT'HIVAC Cutaneous HIV Vaccination · Centre Hospitalier Universitaire Vaudois · European Commission · European Georges Pompidou Hospital
+10 more
· FIT Biotech Ltd. · Fred Hutchinson Cancer Center · Henri Mondor University Hospital · Institut d'Investigacions Biomèdiques August Pi i Sunyer · Istituto Nazionale per le Malattie Infettive "Lazzaro Spallanzani" IRCCS · Medical Research Council · Saint-Louis Hospital, Paris, France · Swiss Government · University College, London · University Medical Center Hamburg-Eppendorf

today NCT02972450 · Ph 1/2 NCT02075983 · Ph 1

20142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 11 trial
Phase 1	NCT02075983	Jun 2013 → Jun 2015	HIV infectious disease	Imperial College London	Unknown	No outcome recorded
Phase 1/21 trial
Phase 1/2	NCT02972450	Feb → Jul 2019	HIV infectious disease	ANRS, Emerging Infectious Diseases	Terminated	No outcome recorded

Also used as a comparator or background therapy in 1 trial

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1/2	NCT02457689 Comparator	Jul 2015 → Jul 2016	HIV infectious disease	Imperial College London	Completed	No outcome recorded

Every value below carries the sentence it was read from. 4 sources stand behind the page.

Field	Value	Cited text
Known as	GTU-MultiHIV B clade	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02457689 ↗ 2 NCT02075983 ↗ NCT02972450 ↗
Known as	GTUMultiHIV B DNA vaccine	“The GTU®MultiHIV B DNA vaccine DNA vaccine encoded a MultiHIV B clade fusion protein to target the cellular response.” PMID 31921170 ↗ Dec 2019
Modality	Vaccine	“The investigational HIV-1 vaccine GTU®-MultiHIV B clade” NCT02075983 ↗
Route	Intramuscular	“two IM injections of 2.0mg GTU®-MultiHIV DNA IM” NCT02075983 ↗